Diabetes of exocrine pancreas

Česká verzia

Authors: Rid Dravecká
Authors place of work: I. interná klinika LF UPJŠ a UNLP Košice
Published in the journal: Forum Diab 2020; 9(3): 184-190
Category: Review Article

Summary

Diabetes mellitus is a group of diseases defined by persistent hyperglycemia. Causes of diabetes include also exocrine pancreatic diseases. Exocrine pancreatic diseases lead to diabetes by varying mechanisms of hyperglycemia. The most common causes are chronic pancreatitis, pancreatic ductal adenocarcinoma, hemochromatosis, cystic fibrosis, and previous pancreatic surgery. Recent literature refers to it as type 3 diabetes. It´s prevalence and clinical importance have been underestimated. The early identification of pancreatogenic diabetes and distinction from the more prevalent type 2 diabetes is clinically significant. Possible mechanisms for increased cancer risk in diabetes include cellular proliferative effects of hyperglycemia, hyperinsulinemia, and abnormalities in insulin/IGF receptor pathways. Despite its differences, no guidelines for therapy have been described. Metformin promotes a survival benefit in individuals with post-pancreatitis diabetes mellitus but not with pancreatic cancer related diabetes. Reverse causality may play a role in the association between insulin use and mortality in pancreatic cancer related diabetes. Metformin treatment reduces the cancer risk in diabetic subjects.

Keywords:

diabetes mellitus 3c type – exocrine pancreas – insulin use – metformin – Pancreatitis

Zdroje

Ewald N, Kaufmann C et al. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev 2012; 28(4): 338–342. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.2260>.
Ewald N, Bretzel RG. Diabetes mellitus secondary to pancreatic diseases (Type 3c) – Are we negleting an important disease? Eur J Intern Med 2013; 24(3): 203–206. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejim.2012.12.017>.
Hart PA, Bellin MD et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol 2016; (3): 226–237. Dostupné z DOI: <http://dx.doi.org/10.1016/S2468–1253(16)30106–6>.
Cui YF, Andersen DK. Pancreatogenic Diabetes: Special Consideration for Mangement. Pancreatology 2011; 11(3): 279–294. Dostupné z DOI: <http://dx.doi.org/10.1159/000329188>.
Cho J, Scragg R, Pandol SJ et al. Antidiabetic Medications and Mortality Risk in Individuals with Pancreatic Cancer – related Diabetes and Postpancreatic Diabetes. A Nationwide Cohort Study. Diabetes Care 2019; 42(9):1675–1683. Dostupné z DOI: <http://dx.doi.org/10.2337/dc19–0145>.
Andersen DK, Andren-Sandberg A, Duell EJ et al. Pancreatitis – Diabetes – Pancreatic Cancer: Summary of an NIDDK-NCI Workshop. Pancreas 2013; 42(8):1227–37. Dostupné z DOI: <http://dx.doi.org/10.1097/MPA.0b013e3182a9ad9d>.
Hart PA, Andersen DK, Mather KJ et al. Evaluation of Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rationale and Methodology for the DETECT Study from the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer. Pancreas 2018; 47(10): 1239–1243. Dostupné z DOI: <http://dx.doi.org/10.1097/MPA.0000000000001168>.
Woodmansey C, McGovern AP, McCullough KA. Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c): A Retrospective Cohort Study. Diabetes Care 2017; 40(11): 1486–1493. Dostupné z DOI: <http://dx.doi.org/10.2337/dc17–0542>.
Roeyen G, DeBlock Ch. A plea for more practical and clinically applicable criteria defining type 3c diabetes. Pancreatology 2017; 17(6): 875. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pan.2017.10.004>.
Andersen DK. The practical importance of recognizing pancreatogenic or type 3c diabetes. Diabetes Metab Res Rev 2012; 28(4): 326–328. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.2285>.
Cui YF, Andersen DK. Diabetes and Pancreatic Cancer 2012; 19(5):F9-F26. <http://dx.doi.org/10.1530/ERC-12–0105>.
Waters AM, Der CJ. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 2018; 8(9): a031435. Dostupné z DOI: <http://dx.doi.org/10.1101/cshperspect.a031435>.
Gao W, Zhou Y, Li Q et al. Analysis of global gene expression profiles suggests a role of acute inflammation in type 3c diabetes mellitus caused by pancreatic ductal adenocarcinoma. Diabetologia 2015; 58(4): 835–844. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–014–3481–8>.